Stryker Corporation (NYSE:SYK) Shares Acquired by Achmea Investment Management B.V.

Achmea Investment Management B.V. increased its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 40.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 49,753 shares of the medical technology company's stock after acquiring an additional 14,391 shares during the quarter. Achmea Investment Management B.V.'s holdings in Stryker were worth $18,520,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SYK. Norges Bank bought a new position in shares of Stryker during the fourth quarter worth about $1,710,744,000. GAMMA Investing LLC lifted its holdings in Stryker by 43,226.8% during the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock worth $772,390,000 after buying an additional 2,070,133 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Stryker in the 4th quarter valued at approximately $353,394,000. FMR LLC raised its position in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after acquiring an additional 727,850 shares in the last quarter. Finally, Proficio Capital Partners LLC increased its stake in Stryker by 52,520.8% during the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock valued at $214,660,000 after purchasing an additional 595,061 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 5.90% of the company's stock.

Stryker Stock Performance

SYK stock opened at $390.67 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19. The business's fifty day moving average is $378.06 and its 200-day moving average is $375.38. The company has a market cap of $149.11 billion, a P/E ratio of 52.79, a price-to-earnings-growth ratio of 2.96 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same period in the previous year, the firm earned $2.50 EPS. Stryker's quarterly revenue was up 11.9% compared to the same quarter last year. Equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker's payout ratio is currently 45.41%.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of recent research reports. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research report on Tuesday, March 4th. Citigroup reaffirmed a "buy" rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Evercore ISI cut their target price on Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Finally, Truist Financial lifted their price target on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.